Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?

Bone Marrow Transplantation volume 35, pages S49–S52 (2005)Cite this article

Summary:

Relapse is the major complication after allogeneic stem cell transplantation (SCT) for acute lymphoblastic leukemia (ALL) in children. Since it has been possible to measure minimal residual disease (MRD) by real-time quantitative polymerase chain reaction, this parameter is used more frequently in the treatment of ALL. In this article, the role of MRD and chimerism in the treatment and monitoring of pediatric transplantation recipients is described. Pre-SCT MRD levels can predict the risk of relapse and can thus be used to adjust treatment. Post-SCT MRD levels and changes in chimerism can predict relapses as well, although not many treatment options are available today, except relying on a graft-versus-leukemia effect mediated by graft-versus-host disease. Finding new treatments will be the challenge for the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. van Dongen JJ, Seriu T, Panzer-Grumayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.

    Article  CAS  PubMed  Google Scholar 

  2. Knechtli CJ, Goulden NJ, Hancock JP et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998a; 92: 4072–4079.

    CAS  PubMed  Google Scholar 

  3. Goulden N, Bader P, van-der-Velden VHJ et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24–29.

    Article  PubMed  Google Scholar 

  4. Krejci O, van-der-Velden VHJ, Bader P et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849–851.

    Article  CAS  PubMed  Google Scholar 

  5. Bruggemann M, van-der-Velden VHJ, Raff T et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 709–719.

    Article  CAS  PubMed  Google Scholar 

  6. Pongers-Willemse MJ, Seriu T, Stolz F et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110–118.

    Article  CAS  PubMed  Google Scholar 

  7. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006–2014.

    Article  CAS  PubMed  Google Scholar 

  8. van-der-Velden VHJ, Wijkhuijs JM, Jacobs DC et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002b; 16: 1372–1380.

    Article  CAS  PubMed  Google Scholar 

  9. Knechtli CJ, Goulden NJ, Hancock JP et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998b; 102: 860–871.

    Article  CAS  PubMed  Google Scholar 

  10. van-der-Velden VHJ, Jacobs DC, Wijkhuijs AJ et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002a; 16: 1432–1436.

    Article  CAS  PubMed  Google Scholar 

  11. Bader P, Beck J, Frey A et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487–495.

    Article  CAS  PubMed  Google Scholar 

  12. Bader P, Holle W, Klingebiel T et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 697–702.

    Article  CAS  PubMed  Google Scholar 

  13. Goulmy E . Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 2004; 10: 1–7.

    Article  CAS  PubMed  Google Scholar 

  14. Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Leiden University Medical Center, Leiden, NL, The Netherlands

    M W Schilham

  2. Clinica Pediatrica Università degli Studi di Milano Bicocca, Monza, IT

    A Balduzzi

  3. University Children's Hospital, Tübingen, GE

    P Bader

Authors
  1. M W Schilham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Balduzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the PD-WP of the EBMT

Corresponding author

Correspondence to M W Schilham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schilham, M., Balduzzi, A., Bader, P. et al. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?. Bone Marrow Transplant 35 (Suppl 1), S49–S52 (2005). https://doi.org/10.1038/sj.bmt.1704847

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704847

Keywords

This article is cited by

Search

Advanced search

Quick links